Navigation Links
Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
Date:1/5/2011

LEXINGTON, Ky., Jan. 5, 2011 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International (CDI), the world's largest producer of human induced pluripotent stem (iPS) cell lines and tissue cells for drug discovery and safety.

The license agreement allows CDI to use Transposagen's piggyBac technology in the creation of its products. The piggyBac technology is a highly versatile non-viral method for genetic engineering and stable transgene expression. "We are pleased to be partnering with CDI," said Dr. Eric Ostertag, President and CEO of Transposagen. "Like Transposagen, their products are revolutionizing the drug discovery process."

"CDI is committed to providing human cells derived from iPS cells in the quality, purity, and quantity required by customers, enabling them to concentrate on generating reliable, reproducible, and predictive data and not on creating the cells themselves," said Bob Palay, CDI CEO and chairman of the board. "Toward that end, CDI continues to seek and license in useful technologies, such as piggyBac, that may help improve our manufacturing capabilities." In addition to its iCell™ Cardiomyocytes product line, CDI is planning to launch hepatocytes, neurons, and endothelial cells in the next year.  

The two companies have also agreed to a research and development collaboration.  Transposagen was granted a research license to any cell or product developed by CDI that uses piggyBac for its creation.  Transposagen, the worldwide leader in genetically modified rats, may use CDI's cells to develop "humanized rats," rats that contain organs predominantly consisting of human-derived cells.  Transposagen is developing products expected to improve drug discovery and development by more accurately predicting human response to potential therapeutics at the pre-clinical stage.

About Transposagen BiopharmaceuticalsTransposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models.  The company's signature products, TKO™ Knockout Rat Models and TGEM™ Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. For more information or to request a custom rat model, visit www.transposagenbio.com.

About Cellular Dynamics International, Inc.Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cells from the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund. CDI's facilities are located in Madison, Wisconsin.  See www.cellulardynamics.com.Contact:Jack Crawford145 Graham Ave.ASTeCC Bldg., Suite A217Lexington, KY 40506859-428-8561
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
2. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
3. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
4. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
5. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
6. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
7. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
10. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
11. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):